This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Abbott Laboratories (ABT)

NYSE: Health Care

Company Income Statement
Dec 2014 Dec 2013 Dec 2012 Dec 2011
Sales 20.25B 21.85B 39.87B 38.85B
Cost of Sales 8.22B 9.11B 12.34B 12.50B
Gross Operating Profit 12.02B 12.74B 27.54B 26.35B
Selling, General, and Administrative Expenses 6.53B 6.94B 12.06B 12.76B
Research & Development 1.34B 1.45B 4.32B 4.13B
Operating Income before D & A (EBITDA) 4.15B 4.35B 11.16B 9.47B
Depreciation & Amortization 1.55B 1.72B 2.78B 3.04B
Interest Income 77.00M 67.00M 79.22M 85.20M
Other Income - Net -8.00M -18.00M -1.31B -108.36M
Special Income / Charges 0.00 0.00 -576.00M -1.34B
Total Income Before Interest Expenses (EBIT) 2.67B 2.68B 6.86B 5.73B
Interest Expense 150.00M 157.00M 592.40M 530.14M
Pre-Tax Income 2.52B 2.52B 6.26B 5.20B
Income Taxes 797.00M 138.00M 299.69M 470.19M
Minority Interest 0.00 0.00 0.00 0.00
Net Income From Continuing Operations 1.72B 2.38B 5.96B 4.73B
Net Income From Discontinued Operations 563.00M 193.00M 0.00 0.00
Net Income From Total Operations 2.28B 2.58B 5.96B 4.73B
Extraordinary Income/Losses 0.00 0.00 0.00 0.00
Income From Cum. Effect of Acct. Change 0.00 0.00 0.00 0.00
Income From Tax Loss Carryforward 0.00 0.00 0.00 0.00
Other Gains / Losses 0.00 0.00 0.00 0.00
Total Net Income 2.28B 2.58B 5.96B 4.73B
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
1.72B 2.38B 6.25B 5.40B
Preferred Dividends
Net Income Available To Common 1.72B 2.38B 5.96B 4.73B
Basic EPS from Continuing Ops. 1.13 1.52 3.79 3.04
Basic EPS from Discontinued Ops. 0.37 0.12 0.00 0.00
Basic EPS from Total Operations 1.50 1.64 3.79 3.04
Basic EPS from Extraordinary Inc. 0.00 0.00 0.00 0.00
Basic EPS from Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
Basic EPS from Tax Loss Carryf'd. 0.00 0.00 0.00 0.00
Basic EPS from Other Gains (Losses) 0.00 0.00 -0.03 -0.01
Basic EPS, Total 1.50 1.64 3.76 3.03
Basic Normalized Net Income/Share 1.13 1.52 3.97 3.47
EPS fr Continuing Ops. 1.12 1.50 3.75 3.02
EPS fr Discontinued Ops 0.37 0.12 0.00 0.00
EPS fr Total Ops. 1.49 1.62 3.75 3.02
EPS fr Extraord. Inc. 0.00 0.00 0.00 0.00
EPS fr Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
EPS fr Tax Loss Carfd. 0.00 0.00 0.00 0.00
EPS fr Other Gains (L) 0.00 0.00 -0.03 -0.01
EPS, Total 1.49 1.62 3.72 3.01
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
1.12 1.50 3.93 3.45
Dividends Paid per Share 0.88 0.56 2.01 1.88
ABT News

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free

ABT Abbott Laboratories

Chart of ABT

Analysts Ratings for ABT

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 9 10 9 9
Moderate Buy 2 2 3 3
Hold 6 5 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET ABT ANALYST REPORT

ABT Chatter

Top Rated Stocks Top Rated Funds Top Rated ETFs